Phagenesis key facts
as of Oct 2026- Developer of a medical device designed to provide treatment of acute dysphagia.
- Phagenesis is valued at approximately $51.3M as of Oct 2026 (last reported valuation).
- It has raised $90.0M.
- Notable investors include MedTech Innovator, British Business Bank, Wellcome Trust, Northern Gritstone, Nestlé Health Science — 11 tracked in total.
- Status: Privately Held (backing).
Phagenesis's last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Phagenesis: the Monday email on marks, rounds and moves
Phagenesis funding rounds
No funding rounds for Phagenesis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Phagenesis
11+Phagenesis valuation
Phagenesis's last reported valuation was $51.3 million in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
Phagenesis investors
11 investors are on record for Phagenesis, including MedTech Innovator, British Business Bank, Wellcome Trust and Northern Gritstone.
About Phagenesis
Developer of a medical device designed to provide treatment of acute dysphagia. The company's device helps harness the brain's capacity for relearning functions that have been lost through brain damage via neuroplasticity or cortical remapping through neurostimulation therapy and offers a non-surgical, personalized treatment using pharyngeal electrical stimulation (PES), enabling patients to restore the neurological control of swallowing and accelerate recovery.
- Sector
- Healthcare
- HQ
- Manchester, United Kingdom
- Founded
- 2007
- Employees
- 65
- Website
- phagenesis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.